Evidence map›Paper›PMID 34648735›Full record

ArticleCell reports2021

In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential.

Brandon Lam, Yu Jui Kung, John Lin, Ssu-Hsueh Tseng, Ya Chea Tsai, Liangmei He, Gianni Castiglione, Emily Egbert, Elia J Duh, Evan M Bloch and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Brandon LamDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Graduate Program in Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Yu Jui KungDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
John LinDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Ssu-Hsueh TsengDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Ya Chea TsaiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Liangmei HeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Gianni CastiglioneDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Emily EgbertDivision of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Elia J DuhDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Aaron A R TobianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Aaron M MilstoneDivision of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; Department of Hospital Epidemiology and Infection Control, The Johns Hopkins Hospital, Baltimore, MD 21205, USA.
Richard B S RodenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Obstetrics and Gynecology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Tzyy-Choou WuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Obstetrics and Gynecology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Molecular Microbiology and Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Chien-Fu HungDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: chung2@jhmi.edu.
Johns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
The role of Albumin-Flt3L-induced cross-presenting dendritic cell expansion in antitumor immunityF31CA236051 · NCI · JOHNS HOPKINS UNIVERSITY · PI LAM, BRANDON KRISHNA · 2019 to 2021
$128k
NCI NIH HHS F31 CA236051NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA237067
6 · The paper itself

Abstract

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads, variants with enhanced virulence and transmissibility have emerged. Although in vitro systems allow rapid characterization, they do not fully recapitulate the dynamic interaction of virions and neutralizing antibodies in the airway. Here, we demonstrate that the N501Y variant permits respiratory infection in unmodified mice. We utilize N501Y to survey in vivo pseudovirus infection dynamics and susceptibility to reinfection with the L452R (Los Angeles), K417N + E484K (South Africa), and L452R + K417N + E484Q (India) variants. Human coronavirus disease 2019 (COVID-19)+ or vaccinated antibody isotypes, titers, variant receptor binding domain (RBD) binding, and neutralization potential are studied, revealing numerous significant correlations. Immune escape of the K417N + E484K variant is observed because infection can be appreciated in the nasopharynx, but not lungs, of mice transferred with low-antibody-tier plasma. Conversely, near-complete protection is observed in animals receiving high-antibody-tier plasma, a phenomenon that can only be appreciated in vivo.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCell LineCOVID-19COVID-19 SerotherapyCricetinaeGenetic VariationHEK293 CellsHumansImmune SystemImmunization, PassiveIn Vitro TechniquesMiceMutationNasopharynxAntibodies, NeutralizingAntibodies, ViralRecombinant ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19immune escapein vivo modelingN501YpseudovirusSARS-CoV-2

Identifiers

PMID34648735
PMCPMC8491932
OpenAlexW3204408617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.